A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen
Open Access
- 1 August 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 38 (8) , 666-671
Abstract
Prostate-specific membrane antigen (PSMA) is an extensively studied antigen for imaging prostate cancer. We prepared a single-chain variable fragment (scFv) of J591, a monoclonal antibody that recognises an external epitope of PSMA, incorporating a His-tag for labelling with 99mTc tricarbonyl, and evaluated its binding using human PCa cell lines. J591(scFv) was expressed in HEK-293T cells and purified by metal ion affinity chromatography, followed by size exclusion chromatography. Stability and monomer/dimer ratios of purified scFv under different storage conditions were analysed by SDS-PAGE and analytical size exclusion chromatography. J591(scFv) was labelled with 99mTc(CO)+3 at 37°C for 60 min. The stability of 99mTc-scFv in human serum was analysed by SDS-PAGE with autoradiography. Cell-binding studies were carried out using PC3LN3 (PSMA negative) and PC3LN3-PSMA (a variant engineered to express PSMA) cell lines. J591(scFv) was most stable to dimerisation on storage at −80°C compared with −20 and 4°C. Radiochemical yields of 85–90% were obtained with the final radiochemical purity of more than 99% after purification by gel filtration. In these small-scale studies, the maximum specific activity achieved was 7 MBq/μg. Liquid chromatography–mass spectrometry showed the formation of 99mTc-J591(scFv), which was radiochemically stable in serum, with no dissociation of 99mTc over 24 h. Cell-binding assays showed specific binding to PSMA-positive cells. J591(scFv) can be radiolabelled with 99mTc(CO)+3 conveniently and efficiently. The labelled product was stable in serum. It showed selective binding to PSMA-positive cells compared with PSMA-negative cells. This potential radiotracer warrants evaluation in PCa xenograft models. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/Keywords
This publication has 22 references indexed in Scilit:
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate CancerClinical Cancer Research, 2015
- Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal AntibodyCurrent Radiopharmaceuticals, 2015
- Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumorsEJNMMI Research, 2015
- 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate CancerJournal of Nuclear Medicine, 2014
- First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate CancerJournal of Nuclear Medicine, 2013
- Indium-111 capromab pendetide in the management of recurrent prostate cancerExpert Review of Anticancer Therapy, 2008
- Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate‐specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological stagingBJU International, 2005
- Update on Fused Capromab Pendetide Imaging of Prostate CancerClinical Prostate Cancer, 2005
- Correlation Between PSMA and VEGF Expression as Markers for LNCaP Tumor AngiogenesisBioMed Research International, 2005
- Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastasesUrology, 1998